Article
Targeting the DNA repair defect of BRCA tumours.
Current opinion in pharmacology - 1 Aug 2005
Turner Nicholas, Tutt Andrew, Ashworth Alan
Abstract excerpt
Carriers of heterozygous mutations in BRCA1 or BRCA2 are strongly predisposed to breast and ovarian cancers. Cancers arising in these individuals have consistently lost the wild-type allele during tumour progression, and are therefore deficient in BRCA1 or BRCA2 function. Both BRCA1 and BRCA2 proteins have been implicated in the repair of double-strand DNA breaks by homologous recombination. This functional role...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
